EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
- Registry ID
- NN9490-8266
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVO NORDISK CANADA INC
- Start date
- 2026-05-11
- Last update
- 2026-03-19
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ALN-6222 IN ADULT PARTICIPANTS WITH OBESITY
- A CLINICAL STUDY TO COMPARE EFFICACY AND SAFETY OF TWO DIFFERENT DOSES OF CAGRISEMA AND SEMAGLUTIDE IN PARTICIPANTS WITH OBESITY WITH OR WITHOUT TYPE 2 DIABETES
- EFFICACY AND SAFETY OF NNC0487-0111 S.C. ONCE-WEEKLY IN PARTICIPANTS WITH OBESITY (AMAZE 1)
- MASTER PROTOCOL: A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OSTEOARTHRITIS KNEE PAIN, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-4)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT, WITHOUT TYPE 2 DIABETES (ENLIGHTEN-1)
View on source registry